UniQure rises on updated interim data from genetic disease study

uniQure

09/07/2024 13:31

** U.S.-listed shares of gene therapy developer uniQure
 UQ1.F   QURE.O  rise 25.7% to $4.75 premarket
    ** Co announces updated 24 months' follow-up data from its
ongoing early-stage study of its experimental therapy to treat
Huntington's disease
    ** Huntington's disease is a rare inherited disease that
affects movement and cognitive functions
    ** Co says patients receiving high-dose of the therapy
showed 80% slowing of disease progression at 24 months, assessed
by a scale that measures symptoms of the disease
    ** Co says the therapy also showed a statistically
significant reduction in levels of a disease-causing protein
    ** In the second half of 2024, co to hold a meeting with the
U.S. FDA to present the updated data and discuss accelerated
approval
    ** Up to last close, stock is down 44.2% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))